INmune Bio Inc. (NASDAQ: INMB) (the
“Company”), a clinical-stage immunology company focused on
developing treatments that harness the patient’s innate immune
system to fight disease, today announces its financial results for
the quarter ended September 30, 2023 and provides a business
update.
Q3 2023 Corporate Highlights:
DN-TNF Platform Highlights (XPro™):
- AD02
blinded randomized program in patients with Early Alzheimer’s
Disease (AD) received authorization of its Clinical Trial
Application (CTA) by the Medicines and Healthcare products
Regulatory Agency (MHRA) to initiate a Phase II trial in Early
Alzheimer’s disease (AD) with XPro™. The U.K. CTA is part of the
Company’s international clinical development strategy for XPro™ in
patients with early AD. The trial is also enrolling patients in
Australia and Canada. Recruitment of the trial is increasing and
the company anticipates results of the Phase II program
towards the end of 2024. Discussions with the FDA remain ongoing,
and we continue to believe the clinical hold will be lifted before
the end-of-year 2023.
-
Announced expansion of novel MRI biomarker data to include grey
matter. Grey matter, the portion of the brain containing nerve cell
bodies, has historically been the focus of Alzheimer’s disease
research and drug development. Previous MRI biomarker analysis from
patients receiving XPro™ for treatment of AD has demonstrated early
changes in white matter that predict presence of neuroinflammation
and response to XPro™ therapy. The new data, reported at the annual
Alzheimer’s Association International Conference (AAIC) in
Amsterdam, Netherlands in July, demonstrates improvement in grey
matter microstructure in patients with AD. The data confirm that
neuroinflammation affects microstructure of both white and gray
matter of the brain. These changes can be quantified in a “virtual
brain biopsy”. Treatment with XPro™ resulted in improvements in
both white and grey matter microstructural elements that may
predict improvements in cognition. The data further validates the
biomarker package associated with the on-going Phase II trial in
patients with Early AD.
- The
findings presented at CTAD demonstrated effective use of home EEG
in patients receiving XPRO for treatment of Alzheimer’s disease.
Changes in P300 and other EEG measures were seen after treatment
with XPRO. These data add to the biomarker package that can be used
to develop XPRO for Alzheimer’s disease and other types of
dementia.
- Data was
presented at the 16th European Meeting on Glial Cells in Health and
Disease in Berlin showing XPro™ promotes remyelination in animal
studies of MS. These data focused on how XPRO promotes microglial
cells to phagocytize myelin debris. Removal of myelin debris is a
key step in promoting oligodendrocyte function. Oligodendrocytes
produce myelin. These data are consistent with the remyelination
that is seen in humans with AD after treatment with XPro. To our
knowledge, XPRO is maybe the only drug therapy to demonstrate
remyelination in humans. Therapies that promote remyelination may
be needed to effectively treat many neurodegenerative diseases
including Alzheimer’s disease.
-
Presented preclinical data at 38th Society of Immunotherapy for
Cancer showing INB03 is an innate immune checkpoint inhibitor.
INB03 neutralizes sTNF, repolarizing tumor-protecting M2
macrophages to M1 anti-tumor macrophages, downregulates expression
of SIRPα, and enhances antibody dependent cellular phagocytosis.
SIRPα, signal-regulatory protein expressed on macrophages, is part
of the SIRPa–CD47 “don’t eat me” pathway, a phagocytosis checkpoint
in macrophages and other innate immune cells.
INKmune™ Platform:
- Remain
on track to launch Phase I/II open label trial using INKmune™ in
metastatic castration-resistant prostate cancer (mCRPC) after
clearance of the IND by the Food & Drug Administration (FDA) in
May. The trial is expected to enroll the first of 30 patients
before end-of-year 2023. Patients will receive three infusions of
INKmune™ as out-patient treatment during the six-month trial.
Three doses of INKmune™ are being tested in a modified Bayesian
Phase I/II trial that uses biomarkers to determine immunologic and
tumor response to INKmune.
- LAUREL,
the INKmune™ trial in high risk MDS and AML has shipped
INKmune™ to the third clinical site in Athens, Greece. The
site is screening patients and expects to treat their first patient
imminently, which will close the first dose cohort. Changing
management of high risk MDS patients in the UK has resulted in
screen failures. The cause of these screen failures has been
identified and addressed to help increase recruiting of patient
into
- LAUREL.
The Company received regulatory approval on October 20th for the
revised enrollment criteria to increase the pool of potential
patients to drive recruitment.
- Pre-clinical work has confirmed in
vitro activity of INKmune™-primed NK cells in nasopharyngeal cancer
and renal cell cancers and non-dilutive funding is being sought to
progress to trial in Q3-4 2024.
- Received a written opinion for the
international patent application titled, “HUMAN T-CELL ACUTE
LYMPHOBLASTIC LEUKEMIA CELL LINE & APPLICATIONS FOR TREATING
CANCER,” an examiner from the International Search Authority at the
United States Patent & Trademark Office (USPTO), authorized by
the World Intellectual Property Organization (WIPO) under the
Patent Cooperation Treaty (PCT), issued a favorable patentability
opinion with respect to novelty, inventive step and industrial
applicability of all claims and concluding that the application
contains patentable subject matter. The application discloses and
claims the novel INB16 cell line on deposit with the American Type
Culture Collection (ATCC), as well as compositions comprising
replication incompetent INB16 cells (“INKmune™”) and methods of
treating cancer in patients by administering INKmune™.
Upcoming Events and Milestones:
-
On track to have FDA lift clinical hold on the use of XPRO to treat
patients with CNS disease in the US by end-of-year 2023.
-
Top-line results for the Phase II XPro™ trial for treatment of
patients with early Alzheimer’s disease with biomarkers of
neuroinflammation are expected end-of-year 2024.
-
Initiate a Phase II trial of XPro™ in patients with
Treatment-Resistant Depression upon resolution of the ongoing FDA
manufacturing review.
-
Webinar on using XPro™ to promote remyelination in
neurodegenerative disease.
-
Additional open-label Phase I trial data of INKmune™ in high-risk
MDS/AML in 2023.
-
Initiation of open-label Phase I/II trial in prostate cancer in Q4
2023 with patient data expected during 2024.
Financial Results for the Quarter Ended September
30, 2023:
- Net loss
attributable to common stockholders for the quarter ended September
30, 2023, was approximately $8.6 million, compared to approximately
$7.7 million during the quarter ended September 30, 2022.
- Research and
development expenses totaled approximately $6.0 million for the
quarter ended September 30, 2023, compared to approximately $5.2
million during the quarter ended September 30, 2022.
- General and
administrative expense were approximately $2.6 million for the
quarter ended September 30, 2023, compared to approximately $2.4
million during the quarter ended September 30, 2022.
- Other expense
was approximately $0.0 million for the quarter ended September 30,
2023, compared to approximately $0.3 million during the quarter
ended September 30, 2022.
- As of September
30, 2023, the Company had cash and cash equivalents of
approximately $41.8 million.
- As of November
1, 2023, the Company had approximately 18.0 million common shares
outstanding.
Earnings Call Information
To participate in this event, dial approximately 5 to 10 minutes
before the beginning of the call. Please ask for the INmune Bio
Third Quarter Conference Call when reaching an operator.
Date: November 1, 2023Time: 4:30 PM Eastern TimeParticipant
Dial-in: 1-877-407-0784Participant Dial-in (international):
1-201-689-8560Conference ID: 13741726
A live audio webcast of the call can be accessed using this link
or
clicking here:https://viavid.webcasts.com/starthere.jsp?ei=1637274&tp_key=e7f5108b08
A transcript will follow approximately 24 hours from the
scheduled call. A replay will also be available through November 8
by dialing 1-844-512-2921 or 1-412-317-6671 (international) and
entering PIN no. 13741726.
About XPro™
XPro™ is a next-generation inhibitor of tumor necrosis factor
(TNF) that is currently in clinical trial and acts differently than
currently available TNF inhibitors in that it neutralizes soluble
TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF
receptors. XPro™ could have potential substantial beneficial
effects in patients with neurologic disease by decreasing
neuroinflammation. For more information about the importance of
targeting neuroinflammation in the brain to improve cognitive
function and restore neuronal communication
visit this section of the INmune Bio’s website.
About INKmune™
INKmune™ is a pharmaceutical-grade, replication-incompetent
human tumor cell line which conjugates to resting NK cells and
delivers multiple, essential priming signals to convert the cancer
patient’s resting NK cells into tumor killing memory-like NK cells
(mlNK cells). INKmune™ treatment converts the patient’s own
NK cells into mlNK cells. In patients, INKmune™ primed tumor
killing NK cells persist for more than 100 days and function in the
hypoxic TME because due to upregulated nutrient and mitochondrial
survival proteins. INKmune™ is a patient friendly that does not
require pre-medication, conditioning or additional cytokine therapy
given to the patients. INKmune™ is easily transported, stored and
delivered to the patient by a simple intravenous infusion as an
out-patient. INKmune™ is tumor agnostic; it can be used to treat
many types of NK-resistant tumors including leukemia, lymphoma,
myeloma, lung, ovarian, breast, renal and nasopharyngeal cancer.
INKmune™ is treating patients in an open label Phase I trial in
high-MDS/AML in the UK and Europe. The company plans an open
label Phase I/II trial in metastatic castration-resistant prostate
cancer in the US this year.
About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ:
INMB), clinical-stage biotechnology company focused on developing
treatments that target the innate immune system to fight disease.
INmune Bio has two product platforms that are both in clinical
trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF)
product platform utilizes dominant-negative technology to
selectively neutralize soluble TNF, a key driver of innate immune
dysfunction and a mechanistic driver of many diseases. DN-TNF
product candidates are in clinical trials to determine if they can
treat cancer (INB03™), Mild Alzheimer’s disease, Mild Cognitive
Impairment and treatment-resistant depression (XPro™). The Natural
Killer Cell Priming Platform includes INKmune™ developed to prime a
patient’s NK cells to eliminate minimal residual disease in
patients with cancer. INmune Bio’s product platforms utilize a
precision medicine approach for the treatment of a wide variety of
hematologic and solid tumor malignancies, and chronic inflammation.
To learn more, please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance
that any specific outcome will be achieved. Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of
1995. Any statements contained in this press release that do
not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations but are subject
to a number of risks and uncertainties. Actual results and the
timing of certain events and circumstances may differ materially
from those described by the forward-looking statements as a result
of these risks and uncertainties. INB03™, XPro1595 (XPro™), and
INKmune™ are still in clinical trials or preparing to start
clinical trials and have not been approved by the US Food and Drug
Administration (FDA) or any regulatory body and there cannot be any
assurance that they will be approved by the FDA or any regulatory
body or that any specific results will be achieved. The factors
that could cause actual future results to differ materially from
current expectations include, but are not limited to, risks and
uncertainties relating to the Company’s ability to produce more
drug for clinical trials; the availability of substantial
additional funding for the Company to continue its operations and
to conduct research and development, clinical studies and future
product commercialization; and, the Company’s business, research,
product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors are
identified and described in more detail in the Company’s filings
with the Securities and Exchange Commission, including the
Company’s Annual Report on Form 10-K, the Company’s Quarterly
Reports on Form 10-Q and the Company’s Current Reports on Form 8-K.
The Company assumes no obligation to update any forward-looking
statements in order to reflect any event or circumstance that may
arise after the date of this release.
About INmune Bio Inc.
INmune Bio Inc. is
a publicly traded (NASDAQ: INMB), clinical-stage biotechnology
company focused on developing treatments that target the innate
immune system to fight disease. INmune Bio has two product
platforms that are both in clinical trials: The Dominant-Negative
Tumor Necrosis Factor (DN-TNF) product platform utilizes
dominant-negative technology to selectively neutralize soluble TNF,
a key driver of innate immune dysfunction and a mechanistic driver
of many diseases. DN-TNF product candidates are in clinical trials
to determine if they can treat cancer (INB03™), Mild Alzheimer’s
disease, Mild Cognitive Impairment and treatment-resistant
depression (XPro™). The Natural Killer Cell Priming Platform
includes INKmune™ developed to prime a patient’s NK cells to
eliminate minimal residual disease in patients with cancer. INmune
Bio’s product platforms utilize a precision medicine approach for
the treatment of a wide variety of hematologic and solid tumor
malignancies, and chronic inflammation. To learn more, please
visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance
that any specific outcome will be achieved. Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of
1995. Any statements contained in this press release that do
not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations but are subject
to a number of risks and uncertainties. Actual results and the
timing of certain events and circumstances may differ materially
from those described by the forward-looking statements as a result
of these risks and uncertainties. INB03™, XPro1595 (XPro™), and
INKmune™ are still in clinical trials or preparing to start
clinical trials and have not been approved by the US Food and Drug
Administration (FDA) or any regulatory body and there cannot be any
assurance that they will be approved by the FDA or any regulatory
body or that any specific results will be achieved. The factors
that could cause actual future results to differ materially from
current expectations include, but are not limited to, risks and
uncertainties relating to the Company’s ability to produce more
drug for clinical trials; the availability of substantial
additional funding for the Company to continue its operations and
to conduct research and development, clinical studies and future
product commercialization; and, the Company’s business, research,
product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors are
identified and described in more detail in the Company’s filings
with the Securities and Exchange Commission, including the
Company’s Annual Report on Form 10-K, the Company’s Quarterly
Reports on Form 10-Q and the Company’s Current Reports on Form 8-K.
The Company assumes no obligation to update any forward-looking
statements in order to reflect any event or circumstance that may
arise after the date of this release.
INmune Bio Contact:David
Moss, CFO (858) 964-3720info@inmunebio.com
Investor Contact:Jason
NelsonCore IR(516) 842-9614 x-823
The following tables summarize our results of operations
for the periods indicated:
INMUNE BIO INC.
CONDENSED CONSOLIDATED BALANCE
SHEETS(In thousands, except share and per share
amounts)(Unaudited)
|
|
September 30,2023 |
|
|
December 31,2022 |
|
ASSETS |
|
|
|
|
|
|
CURRENT ASSETS |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
41,813 |
|
|
$ |
52,153 |
|
Research and development tax credit receivable |
|
|
2,087 |
|
|
|
8,099 |
|
Other tax receivable |
|
|
176 |
|
|
|
362 |
|
Prepaid expenses and other current assets |
|
|
1,535 |
|
|
|
4,027 |
|
Prepaid expenses – related party |
|
|
- |
|
|
|
34 |
|
TOTAL CURRENT ASSETS |
|
|
45,611 |
|
|
|
64,675 |
|
|
|
|
|
|
|
|
|
|
Operating lease – right of use asset |
|
|
444 |
|
|
|
507 |
|
Other assets |
|
|
129 |
|
|
|
99 |
|
Acquired in-process research and development intangible assets |
|
|
16,514 |
|
|
|
16,514 |
|
|
|
|
|
|
|
|
|
|
TOTAL ASSETS |
|
$ |
62,698 |
|
|
$ |
81,795 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES, REDEEMABLE COMMON STOCK AND
STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
CURRENT LIABILITIES |
|
|
|
|
|
|
|
|
Accounts payable and accrued liabilities |
|
$ |
3,675 |
|
|
$ |
5,206 |
|
Accounts payable and accrued liabilities – related parties |
|
|
79 |
|
|
|
9 |
|
Deferred liabilities |
|
|
496 |
|
|
|
616 |
|
Current portion of long-term debt |
|
|
10,000 |
|
|
|
5,000 |
|
Operating lease, current liabilities |
|
|
106 |
|
|
|
87 |
|
TOTAL CURRENT LIABILITIES |
|
|
14,356 |
|
|
|
10,918 |
|
|
|
|
|
|
|
|
|
|
Long-term debt, net |
|
|
2,376 |
|
|
|
9,697 |
|
Long-term operating lease liabilities |
|
|
430 |
|
|
|
526 |
|
Accrued liability – long-term |
|
|
804 |
|
|
|
550 |
|
TOTAL LIABILITIES |
|
|
17,966 |
|
|
|
21,691 |
|
|
|
|
|
|
|
|
|
|
COMMITMENTS AND CONTINGENCIES |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Redeemable common stock, $0.001 par value; 75,697 and 0 shares
issued and outstanding at September 30, 2023 and December 31, 2022,
respectively |
|
|
799 |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
Preferred stock, $0.001 par
value, 10,000,000 shares authorized, 0 shares issued and
outstanding |
|
|
- |
|
|
|
- |
|
Common stock, $0.001 par
value, 200,000,000 shares authorized, 17,945,995 shares issued and
outstanding |
|
|
18 |
|
|
|
18 |
|
Additional paid-in capital |
|
|
157,264 |
|
|
|
151,799 |
|
Accumulated other comprehensive loss |
|
|
(735 |
) |
|
|
(699 |
) |
Accumulated deficit |
|
|
(112,614 |
) |
|
|
(91,014 |
) |
TOTAL STOCKHOLDERS’ EQUITY |
|
|
43,933 |
|
|
|
60,104 |
|
|
|
|
|
|
|
|
|
|
TOTAL LIABILITIES, REDEEMABLE COMMON STOCK AND
STOCKHOLDERS’ EQUITY |
|
$ |
62,698 |
|
|
$ |
81,795 |
|
|
|
|
|
|
|
|
|
|
INMUNE BIO INC.
CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS AND COMPREHENSIVE LOSS(In thousands,
except share and per share
amounts)(Unaudited)
|
|
For the Three Months EndedSeptember
30, |
|
|
For the Nine Months Ended September
30, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
REVENUE |
|
$ |
43 |
|
|
$ |
98 |
|
|
$ |
127 |
|
|
$ |
277 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OPERATING EXPENSES |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General and administrative |
|
|
2,586 |
|
|
|
2,382 |
|
|
|
7,223 |
|
|
|
6,929 |
|
Research and development |
|
|
5,985 |
|
|
|
5,159 |
|
|
|
14,266 |
|
|
|
13,657 |
|
Total operating expenses |
|
|
8,571 |
|
|
|
7,541 |
|
|
|
21,489 |
|
|
|
20,586 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LOSS FROM OPERATIONS |
|
|
(8,528 |
) |
|
|
(7,443 |
) |
|
|
(21,362 |
) |
|
|
(20,309 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OTHER EXPENSE, NET |
|
|
(35 |
) |
|
|
(282 |
) |
|
|
(238 |
) |
|
|
(1,157 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NET LOSS |
|
$ |
(8,563 |
) |
|
$ |
(7,725 |
) |
|
$ |
(21,600 |
) |
|
$ |
(21,466 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per common share – basic and diluted |
|
$ |
(0.48 |
) |
|
$ |
(0.43 |
) |
|
$ |
(1.20 |
) |
|
$ |
(1.20 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding – basic and diluted |
|
|
18,008,295 |
|
|
|
17,945,995 |
|
|
|
17,966,990 |
|
|
|
17,921,036 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
COMPREHENSIVE LOSS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(8,563 |
) |
|
$ |
(7,725 |
) |
|
$ |
(21,600 |
) |
|
$ |
(21,466 |
) |
Other comprehensive loss – foreign currency translation |
|
|
(23 |
) |
|
|
(441 |
) |
|
|
(36 |
) |
|
|
(1,143 |
) |
Total comprehensive loss |
|
$ |
(8,586 |
) |
|
$ |
(8,166 |
) |
|
$ |
(21,636 |
) |
|
$ |
(22,609 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INMUNE BIO INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH
FLOWS (In
thousands)(Unaudited)
|
|
For the Nine Months EndedSeptember
30, |
|
|
|
2023 |
|
|
2022 |
|
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
|
|
|
|
Net loss |
|
$ |
(21,600 |
) |
|
$ |
(21,466 |
) |
Adjustments to reconcile net
loss to net cash used in operating activities: |
|
|
|
|
|
|
|
|
Stock-based compensation |
|
|
5,489 |
|
|
|
5,361 |
|
Accretion of debt discount |
|
|
179 |
|
|
|
171 |
|
Impairment of operating lease – right of use asset |
|
|
- |
|
|
|
89 |
|
Changes in operating assets
and liabilities: |
|
|
|
|
|
|
|
|
Research and development tax credit receivable |
|
|
6,012 |
|
|
|
496 |
|
Other tax receivable |
|
|
186 |
|
|
|
477 |
|
Prepaid expenses |
|
|
2,492 |
|
|
|
(2,321 |
) |
Prepaid expenses – related party |
|
|
34 |
|
|
|
(109 |
) |
Other assets |
|
|
(30 |
) |
|
|
- |
|
Accounts payable and accrued liabilities |
|
|
(1,531 |
) |
|
|
(268 |
) |
Accounts payable and accrued liabilities – related parties |
|
|
70 |
|
|
|
(72 |
) |
Deferred liabilities |
|
|
(120 |
) |
|
|
304 |
|
Accrued liability – long-term |
|
|
254 |
|
|
|
264 |
|
Operating lease liabilities |
|
|
(14 |
) |
|
|
83 |
|
Net cash used in operating
activities |
|
|
(8,579 |
) |
|
|
(16,991 |
) |
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM
FINANCING ACTIVITIES: |
|
|
|
|
|
|
|
|
Net proceeds from sale of common stock |
|
|
775 |
|
|
|
699 |
|
Repayments of debt |
|
|
(2,500 |
) |
|
|
- |
|
Net proceeds from the exercise of warrants |
|
|
- |
|
|
|
30 |
|
Net cash (used in) provided by
financing activities |
|
|
(1,725 |
) |
|
|
729 |
|
|
|
|
|
|
|
|
|
|
Impact on cash from foreign
currency translation |
|
|
(36 |
) |
|
|
(1,143 |
) |
|
|
|
|
|
|
|
|
|
NET DECREASE IN CASH AND CASH
EQUIVALENTS |
|
|
(10,340 |
) |
|
|
(17,405 |
) |
CASH AND CASH EQUIVALENTS AT
BEGINNING OF PERIOD |
|
|
52,153 |
|
|
|
74,810 |
|
CASH AND CASH EQUIVALENTS AT
END OF PERIOD |
|
$ |
41,813 |
|
|
$ |
57,405 |
|
|
|
|
|
|
|
|
|
|
SUPPLEMENTAL
DISCLOSURE OF CASH FLOWS INFORMATION: |
|
|
|
|
|
|
|
|
Cash paid for income taxes |
|
$ |
- |
|
|
$ |
- |
|
Cash paid for interest expense |
|
$ |
1,394 |
|
|
$ |
962 |
|
|
|
|
|
|
|
|
|
|
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Apr 2024 to May 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From May 2023 to May 2024